Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumors.

Future oncology (London, England)·2026
Same author

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions.

JCO precision oncology·2025
Same author

Reflections on Advances in Cancer Research in 2025.

Cancer discovery·2025
Same author

Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer.

JCO oncology practice·2025
Same author

The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Related Experiment Video

Updated: Jun 13, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Emerging Tumor-Agnostic Molecular Targets.

Dedipya Bhamidipati1, Alison M Schram2

  • 1SUNY Downstate Medical Center, Brooklyn, New York.

Molecular Cancer Therapeutics
|September 16, 2024
PubMed
Summary

Molecular profiling reveals shared tumor alterations, enabling biomarker-driven, disease-agnostic cancer drug development. This approach expands therapeutic reach for advanced solid tumors with specific molecular profiles.

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.7K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Related Experiment Videos

Last Updated: Jun 13, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

1.7K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Tumor molecular profiling identifies common genomic and proteomic alterations across diverse cancer types.
  • A disease-agnostic, biomarker-driven strategy enhances the development and accessibility of novel cancer therapeutics.
  • Eight drug-biomarker pairs are currently approved for advanced solid tumors with specific molecular signatures.

Purpose of the Study:

  • To explore the clinical actionability of emerging biomarkers in patients with advanced solid tumors.
  • To highlight the potential of novel therapeutics targeting shared molecular alterations across tumor types.

Main Methods:

  • Review of current literature on molecular profiling in oncology.
  • Analysis of emerging biomarkers and their therapeutic implications.
  • Examination of approved drug-biomarker pairs for advanced solid tumors.

Main Results:

  • Shared genomic alterations, including gene fusions (NRG1, FGFR1/2/3, BRAF, ALK) and mutations (TP53 Y220C, KRAS G12C, FGFR2/3, BRAF non-V600), show therapeutic potential.
  • The disease-agnostic approach facilitates broader application of targeted therapies.
  • Evidence supports the clinical actionability of these biomarkers in various advanced solid tumors.

Conclusions:

  • Biomarker-driven, disease-agnostic drug development is a promising strategy in oncology.
  • Targeting shared molecular alterations can improve treatment outcomes for patients with advanced solid tumors.
  • Continued research into emerging biomarkers will expand therapeutic options.